- Home
- / Millendo Therapeutics
Millendo Therapeutics
Stock Price
$1.1
2021-07-01
Market Capitalization
$20.2 M
2021-07-01
Revenue
$295 K
FY, 2017
Millendo Therapeutics Summary
Company Summary
- Overview
- Millendo Therapeutics is a biopharmaceutical company. It develops a portfolio of disease-modifying therapies and treatments for specialty and orphan endocrine diseases caused by hormone dysregulation. The company merged with OvaScience.
- Type
- Public
- Status
- Closed
- Founded
- 2012
- HQ
- Ann Arbor, MI, US | view all locations
- Website
- http://www.millendo.com/
- Cybersecurity rating
Table of Contents
Key People
Jeffery M. Brinza, Chief Administrative Officer and General Counsel
Pharis Mohideen, Chief Medical Officer
Thomas Hoover, Senior Vice President, Commercial Strategy
LocationsView all
4 locations detected
Ann Arbor, MI HQ
United States
110 Miller Ave Suite 100
Lexington, MA
United States
420 Bedford St #260
Écully, Auvergne-Rhône-Alpes
France
Espace Européen Batiment G, 15 Chemin du Saquin
Lyon, Auvergne-Rhône-Alpes
France
8 Rue Berjon
Millendo Therapeutics Financials
Summary Financials
- Net income (Q3, 2023)
- ($6.8M)
- Cash (Q3, 2023)
- $11.1M
- EBIT (Q3, 2023)
- ($6.6M)
- Enterprise value
- $19.6M